ABT-199 (GDC-0199)
≥99%
- Product Code: 77431
CAS:
1257044-40-8
Properties:
This product is for scientific research only
| Molecular Weight: | 868.44 g./mol | Molecular Formula: | C₄₅H₅₀ClN₇O₇S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
ABT-199, also known as GDC-0199, is primarily used in the treatment of certain types of cancers, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It functions as a selective BCL-2 inhibitor, which helps in promoting apoptosis, or programmed cell death, in cancer cells. This mechanism is especially effective in cancers where BCL-2 proteins are overexpressed, as these proteins typically prevent apoptosis and allow cancer cells to survive. ABT-199 is often employed when other treatments have failed or are not suitable, offering a targeted approach to disrupt the survival of malignant cells. Its use has shown significant promise in improving patient outcomes, particularly in relapsed or refractory cases, making it a valuable option in oncology therapeutics.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | Light Yellow Solid |
| PURITY | 98.5-100 |
| Infrared spectrum | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.025 | 10-20 days | ฿2,790.00 |
+
-
|
| 0.100 | 10-20 days | ฿7,690.00 |
+
-
|
ABT-199 (GDC-0199)
ABT-199, also known as GDC-0199, is primarily used in the treatment of certain types of cancers, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It functions as a selective BCL-2 inhibitor, which helps in promoting apoptosis, or programmed cell death, in cancer cells. This mechanism is especially effective in cancers where BCL-2 proteins are overexpressed, as these proteins typically prevent apoptosis and allow cancer cells to survive. ABT-199 is often employed when other treatments have failed or are not suitable, offering a targeted approach to disrupt the survival of malignant cells. Its use has shown significant promise in improving patient outcomes, particularly in relapsed or refractory cases, making it a valuable option in oncology therapeutics.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :